Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib after allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
ISRCTN44728648Phase 2Completed
- Sponsor
- Grupo Español de Trasplante Hematopoyético
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by Grupo Español de Trasplante Hematopoyético. Primary endpoint: Disease-free survival at 2 years. Started Apr 2010; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN44728648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44728648.